{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:49:16Z","timestamp":1781542156123,"version":"3.54.5"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19k21601"],"award-info":[{"award-number":["19k21601"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17H04079"],"award-info":[{"award-number":["JP17H04079"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17H05087"],"award-info":[{"award-number":["JP17H05087"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19fk0210057h0001"],"award-info":[{"award-number":["19fk0210057h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19fk0410012s0102"],"award-info":[{"award-number":["19fk0410012s0102"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2020.00216","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T04:58:26Z","timestamp":1588913906000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Pattern Recognition Receptor Ligands as an Emerging Therapeutic Agent for Latent HIV-1 Infection"],"prefix":"10.3389","volume":"10","author":[{"given":"Shokichi","family":"Takahama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12977-017-0335-8","article-title":"Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells","volume":"14","author":"Alvarez-Carbonell","year":"2017","journal-title":"Retrovirology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.4049\/jimmunol.172.12.7229","article-title":"Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors","volume":"172","author":"Bafica","year":"2004","journal-title":"J. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4049\/jimmunol.171.3.1123","article-title":"Cutting edge: in vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2","volume":"171","author":"Bafica","year":"2003","journal-title":"J. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nm.4113","article-title":"PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/ni.2118","article-title":"STING-dependent signaling","volume":"12","author":"Barber","year":"2011","journal-title":"Nat. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.it.2013.10.010","article-title":"STING-dependent cytosolic DNA sensing pathways","volume":"35","author":"Barber","year":"2014","journal-title":"Trends Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e01163","DOI":"10.1128\/AAC.01163-19","article-title":"PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy","volume":"63","author":"Bekerman","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nri3479","article-title":"Newly described pattern recognition receptors team up against intracellular pathogens","volume":"13","author":"Broz","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ni.2491","article-title":"STING and the innate immune response to nucleic acids in the cytosol","volume":"14","author":"Burdette","year":"2013","journal-title":"Nat. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.immuni.2016.08.018","article-title":"CD8(+) lymphocytes are required for maintaining viral suppression in SIV-infected macaques treated with short-term antiretroviral therapy","volume":"45","author":"Cartwright","year":"2016","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"30749","DOI":"10.1038\/srep30749","article-title":"The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function","volume":"6","author":"Clutton","year":"2016","journal-title":"Sci. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1172\/JCI86892","article-title":"The host STING pathway at the interface of cancer and immunity","volume":"126","author":"Corrales","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S692","DOI":"10.1016\/S0168-8278(17)31859-7","article-title":"Sustained efficacy and surface antigen seroconversion in the woodchuck model of chronic hepatitis B with the selective toll-like receptor 8 agonist GS-9688","volume":"66","author":"Daffis","year":"2017","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society global scientific strategy: towards an HIV cure 2016","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e127717","DOI":"10.1172\/jci.insight.127717","article-title":"TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia","volume":"4","author":"Del Prete","year":"2019","journal-title":"JCI Insight."},{"key":"B24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1172\/JCI60612","article-title":"PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques","volume":"122","author":"Dyavar Shetty","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/QAD.0000000000002112","article-title":"In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals","volume":"33","author":"Garrido","year":"2019","journal-title":"AIDS"},{"key":"B28","doi-asserted-by":"publisher","first-page":"eaaz2686","DOI":"10.1126\/scitranslmed.aaz2686","article-title":"Multiple roles for HIV broadly neutralizing antibodies","volume":"11","author":"Haynes","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1004287","DOI":"10.1371\/journal.ppat.1004287","article-title":"Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes","volume":"10","author":"Jones","year":"2014","journal-title":"PLoS Pathog."},{"key":"B32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1172\/JCI80566","article-title":"HIV-specific CD8(+) T cells and HIV eradication","volume":"126","author":"Jones","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1084\/jem.194.6.863","article-title":"Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens","volume":"194","author":"Kadowaki","year":"2001","journal-title":"J. Exp. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nri3727","article-title":"Dendritic cell-targeted vaccines\u2013hope or hype?","volume":"14","author":"Kastenmuller","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.virol.2015.02.017","article-title":"RIG-I in RNA virus recognition","volume":"479","author":"Kell","year":"2015","journal-title":"Virology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e122857","DOI":"10.1172\/jci.insight.122857","article-title":"Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer","volume":"3","author":"Kinkead","year":"2018","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/mi.2017.59","article-title":"The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon","volume":"11","author":"Krarup","year":"2018","journal-title":"Mucosal. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ebiom.2019.03.078","article-title":"Priming of HIV-1-specific CD8(+) T cells with strong functional properties from naive T cells","volume":"42","author":"Kuse","year":"2019","journal-title":"EBioMedicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","article-title":"HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure","volume":"48","author":"Kwong","year":"2018","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3851\/IMP2845","article-title":"Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C","volume":"20","author":"Lawitz","year":"2015","journal-title":"Antivir. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.4124","article-title":"Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation","volume":"22","author":"Li","year":"2016","journal-title":"Nat. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"aao4521","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e122673","DOI":"10.1172\/jci.insight.122673","article-title":"Dual TLR2 and TLR7 agonists as HIV latency-reversing agents","volume":"3","author":"Macedo","year":"2018","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/annonc\/mdr030","article-title":"A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer","volume":"23","author":"Manegold","year":"2012","journal-title":"Ann. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41467-019-13837-4","article-title":"Sensing of HIV-1 by TLR8 activates human T cells and reverses latency","volume":"11","author":"Meas","year":"2020","journal-title":"Nat. Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e122940","DOI":"10.1172\/jci.insight.122940","article-title":"Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV","volume":"3","author":"Mylvaganam","year":"2018","journal-title":"JCI Insight"},{"key":"B49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1742-4690-10-119","article-title":"Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1\/2 stimulation","volume":"10","author":"Novis","year":"2013","journal-title":"Retrovirology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1128\/JVI.00222-16","article-title":"A novel toll-like receptor 9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1-infected autologous CD4+ T cells","volume":"90","author":"Offersen","year":"2016","journal-title":"J. Virol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41591-018-0130-7","article-title":"Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound","volume":"24","author":"Okoye","year":"2018","journal-title":"Nat. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e01194","DOI":"10.1128\/JVI.01194-19","article-title":"Activation of latent HIV-1 T cell reservoirs with a combination of innate immune and epigenetic regulators","volume":"93","author":"Palermo","year":"2019","journal-title":"J. Virol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20061496","article-title":"PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J. Exp. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.vaccine.2017.01.053","article-title":"A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response","volume":"35","author":"Probst","year":"2017","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.0105-2896.2004.00144.x","article-title":"Modulating vaccine responses with dendritic cells and Toll-like receptors","volume":"199","author":"Pulendran","year":"2004","journal-title":"Immunol. Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax(R) (Anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"21897","DOI":"10.1074\/jbc.M311609200","article-title":"CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells","volume":"279","author":"Scheller","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ebiom.2019.07.005","article-title":"TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes","volume":"45","author":"Schleimann","year":"2019","journal-title":"EBioMedicine"},{"key":"B62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1089\/nat.2015.0533","article-title":"Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703","volume":"25","author":"Schmidt","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdy259","article-title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","volume":"29","author":"Scully","year":"2018","journal-title":"Ann. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the latent reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity"},{"key":"B65","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1086\/653112","article-title":"Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial","volume":"51","author":"Sogaard","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1128\/JVI.01635-10","article-title":"RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I","volume":"85","author":"Solis","year":"2011","journal-title":"J. Virol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev-med-052716-031710","article-title":"Novel latency reversal agents for HIV-1 Cure","volume":"69","author":"Spivak","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"11284","DOI":"10.1128\/JVI.01595-15","article-title":"Th1\/17 Polarization of CD4 T cells supports HIV-1 persistence during antiretroviral therapy","volume":"89","author":"Sun","year":"2015","journal-title":"J. Virol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.coph.2018.05.003","article-title":"Combination and inducible adjuvants targeting nucleic acid sensors","volume":"41","author":"Temizoz","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e02166","DOI":"10.1128\/JVI.02166-16","article-title":"Toll-like receptor 7 agonist GS-9620 induces HIV expression and HIV-specific immunity in cells from HIV-infected individuals on suppressive antiretroviral therapy","volume":"91","author":"Tsai","year":"2017","journal-title":"J. Virol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/QAD.0000000000002213","article-title":"Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals","volume":"33","author":"Vibholm","year":"2019","journal-title":"AIDS"},{"key":"B77","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","first-page":"13799","DOI":"10.4238\/2015.October.28.42","article-title":"RIG-I detects HIV-1 infection and mediates type I interferon response in human macrophages from patients with HIV-1-associated neurocognitive disorders","volume":"14","author":"Wang","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1189\/jlb.0313158","article-title":"RIG-I activation inhibits HIV replication in macrophages","volume":"94","author":"Wang","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e62074","DOI":"10.1371\/journal.pone.0062074","article-title":"Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients","volume":"8","author":"Winckelmann","year":"2013","journal-title":"PLoS ONE"},{"key":"B81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.critrevonc.2014.12.002","article-title":"MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside","volume":"94","author":"Wittig","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.1038\/s41598-019-42253-3","article-title":"STING agonists activate latently infected cells and enhance SIV-specific responses ex vivo in naturally SIV controlled cynomolgus macaques","volume":"9","author":"Yamamoto","year":"2019","journal-title":"Sci. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00216\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T04:58:29Z","timestamp":1588913909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00216\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":84,"alternative-id":["10.3389\/fcimb.2020.00216"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2020.00216","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"article-number":"216"}}